Propel Drug-Eluting Sinus Implant Family IBUKI Cohort

Inclusion Criteria: * Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements * Patient has, or is intended to receive or be treated with, an eligible Medtronic product * Patient is consented within the enrollment window of the therapy received, as applicable * Patient has a confirmed diagnosis of CRS, and is indicated for FESS per Japan standard practice * FESS is successfully completed without the occurrence of major/significant complications that may confound study results * Successful placement of 2 to 4 corticosteroid-eluting implants in the ethmoid or frontal sinus (1 implant per sinus) in accordance with implant IFUs * NOVAPAK is the only hemostatic packing material placed bilaterally in ethmoid sinuses Exclusion Criteria: * Patient has clinical evidence of disease or a condition expected to compromise survival or ability to complete follow-up assessments through Month 6 (end of study) * Participation is excluded by local law * Patient is currently enrolled in, or plans to enroll in, any concurrent study that may confound the PSR results (i.e., no required intervention that could affect interpretation of all-around product safety and/or effectiveness) * Patient has received biologic medication approved for the treatment of CRSwNP (e.g., dupilumab, mepolizumab) in ≤ 12 weeks prior to the baseline/procedure visit * Patient is contraindicated in accordance with IFUs of PROPEL family implants and/or NOVAPAK